Intravitreal Bevacizumab for Choroidal Neovascular Membrane in Macular Telangiectasia Type 2.

Autor:	Gonzalez Martinez OG; Ophthalmology, University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, USA., Ayala Rodríguez SC; Ophthalmology, University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, USA., Pappaterra-Rodriguez M; School of Medicine, Ponce Health Sciences University, Ponce, USA.; Ophthalmology, University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, USA., Requejo-Figueroa G; Ophthalmology, University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, USA., Oliver AL; Ophthalmology, University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Jun 16; Vol. 15 (6), pp. e40528. Date of Electronic Publication: 2023 Jun 16 (Print Publication: 2023).
DOI:	10.7759/cureus.40528
Abstrakt:	We report a case of macular telangiectasia type 2 with an associated choroidal neovascular membrane and its treatment. A 54-year-old female presented with a history of gradual vision loss in both eyes. A physical exam showed visual acuity of 20/40 in both eyes and significant metamorphopsia in the right eye. A fundus examination of the right eye was remarkable for right-angled vessels in the juxtafoveal region and subretinal fibrosis temporal to the fovea. A fundus examination of the left eye revealed intraretinal crystals in the juxtafoveal region and right-angled vessels. Optical coherence tomography and angiography confirmed the diagnosis of macular telangiectasia type 2 as well as the presence of a choroidal neovascular membrane in the right eye. The patient was treated with 18 intravitreal injections of anti-vascular endothelial growth factor agent in the right eye for two years, with five to six weeks between each treatment, which resulted in the membrane's stability. Our report suggests that anti-vascular endothelial growth factor therapy via intravitreal injection may be beneficial in treating choroidal neovascular membranes in patients with macular telangiectasia type 2. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Gonzalez Martinez et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu